Company news
Zhejiang Medicine Co., Ltd. Class A (SSE:600216) news
Zhejiang Medicine Co., Ltd. Class A news releases on 6ix. Latest, Sep 11, 2024: Announcement on Company's Drug Metaraminol Bitartrate Injection Passing…
Press releases — page 2
Announcement on Company's Drug Metaraminol Bitartrate Injection Passing Consistency Evaluation of Generic Drug
September 10, 2024
Announcement on Convening the 2024 Semi-Annual Performance Briefing
September 2, 2024
Semi-annual Report in 2024
August 22, 2024
Announcement on Obtaining the Drug Registration Certificate of Daptomycin for Injection
August 14, 2024
Announcement on Completing Industrial and Commercial Change Registration and Renewing Business License
July 9, 2024
Announcement on Implementation of Dividend Distribution for 2023
July 2, 2024
Announcement on Implementation of Repurchasing and Canceling Registration of Some Restricted Shares
June 20, 2024
Announcement on Resolutions of 1st Session of 10th Board of Directors
June 19, 2024
Announcement on Resolutions of 2023 Annual General Meeting
June 18, 2024
Notice on Convening 2023 Annual General Meeting
May 27, 2024
Announcement on Result of Electing Employee Supervisors of 10th Board of Supervisors
May 16, 2024
Announcement on Convening 2023 Annual Performance Meeting
May 10, 2024
Announcement on Subsidiary Receiving Approval Notice for Marketing Application of Chemical Active Pharmaceutical Ingredient
April 29, 2024
Announcement on Renewing Engagement of Accounting Firm
April 25, 2024